Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0)
Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0)
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0)
Statut
Status :
Terminé
Type d'étude
Phase III
Age Min.
18
Ans
Age Max.
75
Ans
Genre
Femme
Aire thérapeutique :
Oncologie
Maladie :
Cancer du sein
Traitement :
Vinflunine (Javlor®)
Phase :
Phase III
Date de début de l'étude :
01 Juillet 2009
End date :
30 Janvier 2014
Identifiant de l'essai :
L00070 IN 308 B0
Identifiant EudraCT/CTIS :
2009-011118-47
Identifiant CT.gov :
NCT01091168
Envoyer par email